Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures



    Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures

PR Newswire

CAMBRIDGE, Mass., May 22, 2013

CAMBRIDGE, Mass., May 22, 2013 /PRNewswire/ -- Flagship Ventures, a leading
venture capital and venture creation firm focused on healthcare and
sustainability, today announced the appointment of Stephane Bancel as a Senior
Partner. In this role, Mr. Bancel will provide strategic counsel and support
to portfolio companies.

In addition to working closely with companies in the Flagship portfolio, Mr.
Bancel also serves as President and Chief Executive Officer of Moderna
Therapeutics, a Flagship VentureLabs™ - founded company.  Moderna is
pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality
that produces human proteins or antibodies inside the patient, within the
patient's cells. This allows the in vivo expression of virtually any
therapeutic protein for intracellular or systemic action. He is also Executive
Chairman of the board for BG Medicine, Inc. (NASDAQ: BGMD), a Flagship
portfolio company focused on the discovery, development and commercialization
of novel, biomarker-based diagnostics to improve patient outcomes and contain
healthcare costs.

"Stephane brings with him a wealth of management experience and expertise in
the development and commercialization of medical diagnostic tools and
technologies as well as expertise in the pharmaceuticals industry," said
Noubar Afeyan, Managing Partner and Chief Executive Officer of Flagship
Ventures.  Under Mr. Bancel's leadership, Moderna has entered into one of the
largest preclinical biotech-pharma deals in the industry's 35 year history
with AstraZeneca. The recently announced partnership agreement involves up to
40 options to drug products and $420M in up front and technology milestone
payments. Dr. Afeyan added, "having worked together with Stephane for over
three years now at BG Medicine and Moderna, I look forward to seeing his
commercial mindset and strategic insights applied more broadly to Flagship's
investment strategy as well as to the growth and success of our portfolio
companies." 

Mr. Bancel said "What attracted me to Flagship Ventures was the team's depth
of experience and knowledge in the life sciences industry, as well as the
firm's unique philosophy and approach to realizing entrepreneurial
innovation." He continued, "I look forward to building on Flagship's growing
reputation as one of the preeminent innovators in the life sciences
ecosystem."

Prior to joining Flagship, Mr. Bancel served as Chief Executive Officer of
bioMerieux (NYSE Euronext: BIM.PA), a world leader in the diagnostics
industry. During his five years leading the company, he accelerated the sales
growth rate, enhanced its position as a global leader in clinical microbiology
and re-accelerated its immunoassay franchise by focusing on high medical value
biomarkers. Under his leadership, the company's market capitalization nearly
doubled despite the broader economic downturn.

Previously, Mr. Bancel was Managing Director of Eli Lilly in Belgium and
Executive Director of Global Manufacturing Strategy and Supply Chain at Eli
Lilly in Indianapolis. He earned a Master of Engineering from Ecole Centrale
Paris, a Master of Science in Chemical Engineering from the University of
Minnesota and an MBA from Harvard Business School. In 2009, Mr. Bancel was
elected a Young Global Leader by the World Economic Forum. He was elected Best
CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the
Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL
Study.

About Flagship Ventures
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The
firm operates through two synergistic units: VentureLabs™ which invents and
launches transformative companies, and Venture Capital, which finances and
develops innovative, early-stage companies. Founded in 2000, and based in
Cambridge, Massachusetts, Flagship Ventures manages over $900 million in
capital. The Flagship team is active in three principal business sectors:
therapeutics, health technologies and sustainability/clean technology. Past
successful Flagship portfolio companies include:  Accuri Cytometers (acquired
by Becton, Dickinson and Company), Adnexus (acquired by Bristol-Myers Squibb),
Hypnion (acquired by Eli Lilly), AVEO (NASDAQ: AVEO), BG Medicine (NASDAQ:
BGMD), Tetraphase (NASDAQ: TTPH), Receptos (NASDAQ: RCPT) and Morphotek
(acquired by Eisai).  Additional notable portfolio companies include: 
AeroDesigns, Affinnova, Agios, BIND Therapeutics, Joule Unlimited, Quanterix,
and Moderna Therapeutics.  For more information, please visit
www.flagshipventures.com.

 

Contact:
For Flagship Ventures:  Rachel Brenner
                        Ruder Finn
                        212.715.1623
                        flagship@ruderfinn.com

 

SOURCE Flagship Ventures

Website: http://www.flagshipventures.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement